TrialDrug design, development and therapy2022

Co-Administration with Voriconazole Doubles the Exposure of Ruxolitinib in Patients with Hematological Malignancies.

Yingxin Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.